Hypothesis

Mitochondrial NAD+ depletion in aged intestinal epithelial cells initiates tight junction disassembly independent of microbiome composition, thereby triggering systemic inflammaging.

Mechanistic Rationale

Aging is associated with a progressive decline in cellular NAD+ levels, particularly in tissues with high metabolic demand such as the gut epithelium [3]. NAD+ is a essential cofactor for sirtuin enzymes (SIRT1, SIRT3) that regulate mitochondrial function, oxidative stress responses, and the stability of tight junction proteins through deacetylation of zonula occludens-1 (ZO-1) and occludin [1]. When NAD+ falls, SIRT1 activity diminishes, leading to hyperacetylation of ZO-1 and occludin, which promotes their internalization and degradation at the apical membrane. This process increases paracellular permeability before any measurable shift in microbial taxa occurs.

Elevated permeability allows translocation of microbial products (LPS, peptidoglycan) and host-derived metabolites (advanced glycation end‑products like CML) into the lamina propria and circulation, activating innate immune receptors on macrophages and endothelial cells. The resulting cytokine surge (IL-6, TNF‑α) fuels systemic inflammaging and can further suppress epithelial NAD+ synthesis via CD38 upregulation, creating a feed‑forward loop.

Testable Predictions

1. Restoring epithelial NAD+ will preserve barrier integrity despite an aged microbiome.

   • Experiment: Treat aged mice with an intestine‑targeted NAD+ precursor (e.g., nicotinamide riboside conjugated to a gut‑restricted carrier) or epithelial‑specific overexpression of NAMPT. Measure zonulin, FITC‑dextran permeability, and tight junction protein localization after 4 weeks. Expect normalization of barrier metrics to young‑mouse levels even when fecal microbiota transplantation from aged donors is performed.
   • Falsification: If barrier leakiness persists despite NAD+ restoration, the hypothesis is weakened.

2. SIRT1 activation downstream of NAD+ will directly stabilize ZO-1/occludin at the membrane.

   • Experiment: Use aged intestinal organoids treated with a SIRT1 activator (SRT2104) and assess protein acetylation status by immunoprecipitation followed by Western blot for acetyl‑lysine on ZO-1 and occludin. Predict reduced acetylation and increased membrane fraction.
   • Falsification: No change in acetylation or membrane localization despite SIRT1 activation would challenge the mechanistic link.

3. Blocking NAD+ depletion in young mice will accelerate age‑like barrier loss.

   • Experiment: Administer CD38 agonist or inhibit NAMPT in young mice for 8 weeks. Assess tight junction protein levels, permeability, and circulating endotoxin. Anticipate early onset of leakiness and inflammaging markers comparable to naturally aged controls.
   • Falsification: Lack of accelerated barrier dysfunction would suggest NAD+ decline is not sufficient.

Implications

If validated, this hypothesis shifts the primary inflammaging driver from a "messy" microbiome‑centric view to a cell‑intrinsic metabolic defect in the gut epithelium. It predicts that interventions targeting epithelial NAD+ metabolism (nutraceuticals, gene therapy, or SIRT1 agonists) could break the gut‑brain axis amplification loop without requiring microbiome remodeling, offering a more tractable avenue for attenuating age‑related inflammation and neuro‑degeneration.